<DOC>
	<DOCNO>NCT00317005</DOCNO>
	<brief_summary>Homocysteine recently gain access category risk factor development atherosclerotic cardiovascular disease general population . Chronic renal failure patient , even introduce dialysis therapy almost universal elevation serum homocysteine ; dialysis mortality 50 % related cardiovascular disease might speculate , contribution potentially toxic level aminoacid homocysteine .</brief_summary>
	<brief_title>Uremic Hyperhomocysteinemia -A Folate Trial Possible Prevention Cardiovascular Events</brief_title>
	<detailed_description>We conduct double blind , randomize , placebo control trial , two year , enrol , simultaneously , 186 end-stage kidney disease patient cause , old 18 year age , stable hemodialysis , assign receive either oral folic acid 10 mg three time week post dialysis session , nurse supervision identical appear placebo entire lenght study , april 2003 march 2005 . The two group similar baseline clinical laboratory characteristic . There loss follow-up . At admission , homocysteine serum level 13,9 umol/L 96.7 % ( median 25.0 , range 9.3-104.0 ) five case normal level ; homocysteine remain elevated 6 , 12 24 month receive placebo ; folate treatment significantly decrease total homocysteine level median value 10.5 umol/L ( 2.8 - 20.3 ) remain level entire study time ( P &lt; 0.001 ) ; every one alive test six month , sixty eight either transplant ( 15 ) die ( 53 ) cardiovascular disease ( seventeen folic acid group twenty one placebo ( P &gt; 0.05 ) cause ( 15 ) , include study . Intima-media wall thickness blind measured common carotid artery decrease 1.94+-0,59 mm 1.67+-0.38 ( P &lt; 0.001 ) folate therapy become thicker , 1.86+-0.41 2.11+-0.48 mm placebo group . In conclusion , folate treatment two year effective modify cardiovascular death non fatal cardiovascular event sample population chronic uremia ; however , ultrasonographic evaluation common carotid artery intima-media wall thickness entry twenty four month later unequivocally show significant thickness decrease supervise folate intake . Earlier prescription folic acid might benefit patient chronic renal failure , prevent cardiovascular deterioration</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Hyperhomocysteinemia</mesh_term>
	<mesh_term>Uremia</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Patients stable hemodialysis 4 month Eighteen year age older Potential kidney transplant live donor near future Severe cardiovascular disease Cancer active inflammation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2005</verification_date>
	<keyword>hemodialysis</keyword>
	<keyword>chronic uremia</keyword>
	<keyword>hyperhomocysteinemia</keyword>
	<keyword>folate</keyword>
</DOC>